(Q34619384)

3 August 2017

1 reference

title

Hepatitis C advances in antiviral therapy: what is accepted treatment now? (English)

1 reference

3 August 2017

1 reference

John G McHutchison

1

1 reference

PubMed ID

11982724

3 August 2017

language of work or name

1 reference

1 April 2002

1 reference

Journal of Gastroenterology and Hepatology

3 August 2017

1 reference

3 August 2017

17

1 reference

3 August 2017

4

1 reference

3 August 2017

431-441

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

The role of liver biopsy in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Hepatitis C virus resistance to antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Hepatitis C in asymptomatic blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02777.X

10.1046/J.1440-1746.2002.02777.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11982724